MediWound Ltd. (MDWD)
$10.92
+0.21 (+1.96%)
Rating:
Recommendation:
Buy
| Symbol | MDWD |
|---|---|
| Price | $10.92 |
| Beta | 0.980 |
| Volume Avg. | 0.06M |
| Market Cap | 103.463M |
| Shares () | - |
| 52 Week Range | 8.05-17.08 |
| 1y Target Est | - |
| DCF Unlevered | MDWD DCF -> | |
|---|---|---|
| DCF Levered | MDWD LDCF -> | |
| ROE | 2027.61% | Strong Buy |
| ROA | -57.03% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 1626.15% | Strong Buy |
| P/E | -3 | |
| P/B | 1,545.51 | Strong Buy |
Latest MDWD news
About
Download (Excel)MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.